The USPTO updates patent term adjustment rules *

USA - May 22 2013
On April 1, 2013, the USPTO published interim final rules that implemented changes to patent term adjustment (PTA) provisions mandated by the AIA…

Co-authors: Lisa Adams, William C. Geary, Ronald E. Cahill, Peter Nils Baylor, Lauren Ingegneri.

Supreme Court remands Myriad for reconsideration in light of Mayo *

USA - March 28 2012
Following close on the heels of last week’s controversial decision in Mayo Collaborative Services v. Prometheus Laboratories, the United States Supreme Court sent another hotly contested biotech case back down for further consideration by a lower federal court.

Co-authors: Lydia G. Olson, Thomas J. Engellenner, Konstantin M. Linnik.

Supreme Court holds Prometheus’ diagnostic method claim unpatentable *

USA - March 21 2012
On March 20, 2012, the United States Supreme Court unanimously reversed the Federal Circuit in a long-awaited decision that may have broad-reaching effects on diagnostic method patents, as well as personalized medicine patents.

Co-authors: Lydia G. Olson, Thomas J. Engellenner, Konstantin M. Linnik, Reza Mollaaghababa, George A. Xixis.

FDA issues “biosimilars” draft guidelines *

USA - February 10 2012
On February 9, 2012, the U.S. Food and Drug Administration (FDA) issued three draft guidance documents– the first since the Biologics Price Competition and Innovation Act passed in March 2010 – for the development of biosimilars.

Co-authors: Maria D. Buckley, Konstantin M. Linnik.